Brain patch trial aims to sharpen thinking in schizophrenia

NCT ID NCT06502964

Recruiting now Symptom relief Sponsor: Alto Neuroscience Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a skin patch called ALTO-101 can improve cognitive function in people with schizophrenia who have thinking problems. About 82 participants will receive either the active patch or a placebo, then switch after a period. The main goal is to see changes in brain wave activity linked to cognition, along with safety and tolerability.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ALTO-101
What this could lead to: If successful, this could point toward a new treatment for cognitive problems in schizophrenia, potentially improving thinking and daily function.
What could go wrong: This is an early Phase 2 trial with only 82 people. It measures brain activity, not real-world thinking, so even positive results may not translate to meaningful benefits. Side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Cognitive Dysfunction schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COGNITIVE IMPAIRMENT SCHIZOPHRENIA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Site 5015
RECRUITING

Tampa, Florida, 33629, United States
Site 5035
RECRUITING

Walnut Creek, California, 94596, United States
Site 5038
RECRUITING

Garden Grove, California, 92845, United States
Site 5056
RECRUITING

Chicago, Illinois, 60640, United States
Site 5060
RECRUITING

Hollywood, Florida, 33024, United States
Site 5062
RECRUITING

Gaithersburg, Maryland, 20877, United States
Site 5063
RECRUITING

Los Angeles, California, 90015, United States
Site 5064
RECRUITING

Snellville, Georgia, 30078, United States
Site 5077
RECRUITING

New York, New York, 10032, United States
Site 5106
RECRUITING

Orange, California, 92868, United States
Site 5108
RECRUITING

New York, New York, 10027, United States
Site 5109
WITHDRAWN

New York, New York, 10035, United States
Site 5124
RECRUITING

Belmont, Massachusetts, 02478, United States
Site 5126
RECRUITING

White Plains, New York, 10605, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.